Merrion Pharma moves to next stage of drug research programme with Nova Nordisk
Merrion Pharmaceuticals Plc. said it has started the next stage of an
oral drug delivery research collaboration programme with Novo Nordisk.
This follows completion of several oral feasibility studies combining
Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral
drug delivery technology with Novo Nordisk compounds. In continuation
of this collaboration, Merrion will now complete the development of solid
dosage forms with GIPET for additional testing, the company said.
|
Home